Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma

Affiliations

• ¹ Department of Medical Specialties, Gastroenterology Unit, University of Modena & Reggio Emilia and Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, Modena, Italy.
• ² Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
• ³ Internal Medicine, Ospedale di Faenza, Faenza, Italy.
• ⁴ Unit of statistical and methodological support to clinical research, University of Modena and Reggio Emilia, AOU Modena, Italy.
• ⁵ Radiology Department, Azienda Ospedaliero-Universitaria, Modena, Italy.
• ⁶ Liver Transplant Center, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, Modena, Italy.
• ⁷ Pathology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
• ⁸ Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.